YH006 / Biocytogen - LARVOL DELTA

YH006: a next-generation CTLA-4×OX40 Treg antagonist, demonstrates superior tumor-infiltrating Treg-depletion efficacy and favorable manufacturability (AACR 2025) - "Ongoing CMC process development has a titer of over 6 g/L at the 20 L scale, and the overall purification yield of >80%. YH006 also has consistent quality from research cell bank to passage 90, suggesting excellent developability."

Clinical • IO biomarker • Oncology • CD8 • CTLA4

YH006, a fully human Treg-depleting CTLA-4×OX40 bispecific antibody, demonstrates superior preclinical efficacy and favorable developability (SITC 2023) - "1 2 Although the first generation Treg-depleting CTLA-4 antibody ipilimumab has shown clinical efficacy, its use, particularly in combination with PD-1 inhibitors, has been associated with severe immune-related adverse events. YH006 has consistent quality from research cell bank (RCB) to passage 97. Conclusions YH006 demonstrated superior anti-tumor efficacy across several tumor models and excellent physiochemical properties, which make it a promising candidate for further development as a cancer treatment."

IO biomarker • Preclinical • Oncology • CD8 • CTLA4 • FCGR3A